arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

60 DEGREES PHARMACEUTICALS, INC.

SXTP
$1.16 ▼ -0.01 (-0.86%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

60 DEGREES PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.0M
Dividend Yield
Revenue Growth -0.9%
Op. Margin None
ROIC -33.2%
FCF / Share $-1.61
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity 0.03
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$162.09K
↓ -0.9%
Net Income Profit after all expenses
$-2.09M
↓ -11.3%
FCF / Share Free cash flow per share
$-1.61
↓ -28.8%
Long-Term Debt Long-term obligations
$150.03K
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
47
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters